Clinical Leukemia最新文献_第2页

New Insights into the Molecular Pathogenesis of Bcr-Abl–Negative Myeloproliferative Disorders bcr - abl阴性骨髓增生性疾病分子发病机制的新认识

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.n.004

Isabelle Plo , Ronan Chaligné , Chloé James , William Vainchenker

引用次数: 0

The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia 造血干细胞移植在成人急性髓性白血病中的作用

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.N.006

M. Hamadani, W. Blum

{"title":"The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Myeloid Leukemia","authors":"M. Hamadani, W. Blum","doi":"10.3816/CLK.2009.N.006","DOIUrl":"https://doi.org/10.3816/CLK.2009.N.006","url":null,"abstract":"Abstract Advances in understanding of the molecular basis of acute myeloid leukemia (AML) are finally beginning to allow tailoring of therapy for patients based on relapse risk. Although remission-induction therapy for most patients today remains predominantly “one-fits-all” cytarabine-based chemotherapy, postremission treatments are becoming more individualized based on cytogenetic or molecular markers of disease. Successive cooperative group trials over the past decade have helped to clarify a role for allogeneic hematopoietic stem cell transplantation (HSCT) for patients with AML in first remission based on cytogenetic risk stratification. More recently, molecular risk stratification has also been helpful in identifying patients who benefit from early transplantation. Herein, we review the current state of allogeneic and autologous HSCT in AML, discuss the role for transplantation in patients with normal-karyotype leukemia, and provide practical recommendations for postremission strategies for AML in first complete remission. We also discuss the role for HSCT in advanced AML, for patients lacking suitable donors, and in older adults with reduced-intensity conditioning.","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"80 1","pages":"47-57"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82400708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights from the 2008 Meeting of the American Society of Hematology San Francisco, CA; December 6–9, 2008 2008年美国血液学会旧金山会议要点;2008年12月6日至9日

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.n.001

Marissa Shrader PhD, Bing-e Xu PhD, Jorge E. Cortés MD, Stefan Faderl MD

引用次数: 0

Telomere Biology in T Cells: An Important Brake on the Road of Their Life Span? T细胞的端粒生物学:它们寿命之路上的一个重要刹车?

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.n.005

Alexander Röth , Gabriela M. Baerlocher

引用次数: 0

MicroRNAs: The jack of all trades microrna:万事通

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.N.003

S. Rehman, G. Baldassarre, G. Calin, M. Nicoloso

引用次数: 2

Central Nervous System Relapse in Acute Promyelocytic Leukemia: Two Cases and a Systematic Review 急性早幼粒细胞白血病的中枢神经系统复发:2例及系统回顾

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.n.007

Michael B. Tomblyn , Kathryn E. Dusenbery , Marcie R. Tomblyn

{"title":"Central Nervous System Relapse in Acute Promyelocytic Leukemia: Two Cases and a Systematic Review","authors":"Michael B. Tomblyn , Kathryn E. Dusenbery , Marcie R. Tomblyn","doi":"10.3816/CLK.2009.n.007","DOIUrl":"https://doi.org/10.3816/CLK.2009.n.007","url":null,"abstract":"<div><p>Central nervous system (CNS) relapse in patients with acute promyelocytic leukemia (APL) is an uncommon event but increasingly reported in the all-<em>trans</em>-retinoic acid (ATRA) era. No standard of care for treating these patients currently exists. We describe 2 cases and review previous reports. Review of the medical literature revealed 61 additional patients, ranging in age from 3.5 to 73 years (median, 39 years). Leukocyte count at initial diagnosis ranged from 1.3 to 307 × 10<sup>9</sup>/L (median, 25.6 × 10<sup>9</sup>/L). Nearly all received ATRA first-line. Only 36% of the relapses were isolated to the CNS, and 86% of patients suffered from neurologic symptoms. Patients were treated with intrathecal chemotherapy alone, radiation alone, or both. In total, 75% of patients treated achieved CNS remission. The success rate of achieving CNS remission by combining radiation and intrathecal chemotherapy was 100%, superior to either modality alone (50% and 75%, respectively). All patients treated with craniospinal radiation were alive and free of disease at 1 year. Patients with APL should be fully evaluated at onset of new neurologic symptoms. Patients with APL with CNS relapse warrant systemic workup because most will not have isolated disease.</p></div>","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"3 1","pages":"Pages 58-64"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2009.n.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91678968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Central nervous system relapse in acute promyelocytic leukemia: Two cases and a systematic review 急性早幼粒细胞白血病的中枢神经系统复发:2例及系统回顾

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.N.007

M. Tomblyn, K. Dusenbery, M. Tomblyn

{"title":"Central nervous system relapse in acute promyelocytic leukemia: Two cases and a systematic review","authors":"M. Tomblyn, K. Dusenbery, M. Tomblyn","doi":"10.3816/CLK.2009.N.007","DOIUrl":"https://doi.org/10.3816/CLK.2009.N.007","url":null,"abstract":"Abstract Central nervous system (CNS) relapse in patients with acute promyelocytic leukemia (APL) is an uncommon event but increasingly reported in the all-trans-retinoic acid (ATRA) era. No standard of care for treating these patients currently exists. We describe 2 cases and review previous reports. Review of the medical literature revealed 61 additional patients, ranging in age from 3.5 to 73 years (median, 39 years). Leukocyte count at initial diagnosis ranged from 1.3 to 307 × 109/L (median, 25.6 × 109/L). Nearly all received ATRA first-line. Only 36% of the relapses were isolated to the CNS, and 86% of patients suffered from neurologic symptoms. Patients were treated with intrathecal chemotherapy alone, radiation alone, or both. In total, 75% of patients treated achieved CNS remission. The success rate of achieving CNS remission by combining radiation and intrathecal chemotherapy was 100%, superior to either modality alone (50% and 75%, respectively). All patients treated with craniospinal radiation were alive and free of disease at 1 year. Patients with APL should be fully evaluated at onset of new neurologic symptoms. Patients with APL with CNS relapse warrant systemic workup because most will not have isolated disease.","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"1 1","pages":"58-64"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87466014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia 急性髓系白血病临床试验的入组标准

Clinical Leukemia Pub Date : 2009-02-01 DOI: 10.3816/CLK.2009.N.002

G. Schiller, M. Sekeres

{"title":"Enrollment Criteria for Clinical Trials in Acute Myeloid Leukemia","authors":"G. Schiller, M. Sekeres","doi":"10.3816/CLK.2009.N.002","DOIUrl":"https://doi.org/10.3816/CLK.2009.N.002","url":null,"abstract":"Abstract Emerging diagnostic and therapeutic developments give insight into the heterogeneous disease biology of acute myeloid leukemia (AML) and provide valuable prognostic information regarding response to therapies and targets for investigational treatments. Our understanding of AML has evolved from morphologic and cytochemical distinctions to cytogenetics-based classification systems. The most recent evolutionary step has been the recognition of the prognostic importance of pathobiologic variations, such as in FLT3 , NPM, and c-Kit; and of clinical disease features, particularly age, de novo versus secondary disease, and remission status. Therapies designed to reverse or inhibit the mechanisms that appear to cooperate in the AML pathobiologic pathway have been developed, including those that target Bcl-2, Ras, hypermethylation, heat shock protein, multidrug resistance efflux pumps, tyrosine kinase activation, histone deacetylation, and FLT3 . Despite this progress, clinical features still serve as the platform for entry into clinical trials of novel agents. As the driving mechanisms of leukemia pathogenesis become further defined, and the inhibition of said mechanisms at a molecular level are correlated to clinical response, future studies should enroll patients on the basis of these molecular features, perhaps in isolation of clinical features, as variables such as age and secondary disease are intermediate markers for underlying pathobiology.","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"13 1","pages":"14-19"},"PeriodicalIF":0.0,"publicationDate":"2009-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84131016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of Anagrelide on JAK2 Mutational Status in Patients with Essential Thrombocythemia 阿那格列特对原发性血小板增多症患者JAK2突变状态的影响

Clinical Leukemia Pub Date : 2008-11-01 DOI: 10.3816/CLK.2008.n.038

Emma Cacciola, Ernesto Di Francesco, Francesca Pezzella, Daniele Tibullo, Rossella Cacciola

引用次数: 4

Isolated Granulocytic Sarcoma: Case Reports of Three Rare Presentations and Review 孤立性粒细胞肉瘤:三例罕见病例报告及回顾

Clinical Leukemia Pub Date : 2008-11-01 DOI: 10.3816/CLK.2008.n.039

Eunpi Cho , Joshua Schiffer , Kathleen Murphy , B. Douglas Smith

引用次数: 0